To clarify, the total financial benefit to CytoD

To clarify, the total financial benefit to CytoDyn Inc. from the settlement with Amarex can be broken down as follows:

1. **$12,000,000 payment by Amarex**:
- $10,000,000 paid on execution of the Settlement Agreement.
- $2,000,000 to be paid on or before July 2, 2025.

2. **$6,500,000 return of the Company’s cash collateral** provided as security to the surety.

3. **$14,000,000 crediting of amounts claimed by Amarex** against the Company’s outstanding balance, reducing it to zero.

However, the $14,000,000 credited against the Company’s outstanding balance is not a direct payment but rather a cancellation of the debt owed by CytoDyn to Amarex. Thus, the actual cash or cash-equivalent benefits are:

\[ \$12,000,000 + \$6,500,000 = \$18,500,000 \]

Therefore, the total direct monetary benefit is $18,500,000, while the overall financial impact, including the cancellation of the $14,000,000 debt, amounts to $32,500,000.

Daniel Rizzo
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™

Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )

Website: FireGateBiotech.com
(For official updates and correspondence — I will no longer be posting here or responding via DMs)

Contact FireGate Biotech


— Jeremiah 51:36